<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04076527</url>
  </required_header>
  <id_info>
    <org_study_id>2.0</org_study_id>
    <nct_id>NCT04076527</nct_id>
  </id_info>
  <brief_title>Prospective, Multicenter Cohort Study on Primary Biliary Cholangitis</brief_title>
  <acronym>PBC-Cohort</acronym>
  <official_title>Prospective, Multicenter Cohort Study on Primary Biliary Cholangitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zentrum für Klinische Studien Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Intercept Pharma Europe Limited (IPEL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical care center for Gastroenterology, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute for Interdisciplinary Medicine, Hamburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leberhilfe Projekt gUG, Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The German PBC Cohort is a multi-centric, observational (non-interventional) study with three
      parallel groups. The main objective of this observational study is to describe the course of
      Primary biliary cholangitis (PBC) in patients in Germany under routine treatment with
      approved drugs. Therefore, the effectiveness and safety/tolerability of PBC treatment options
      in a real-life setting will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease. The
      course of the disease is characterized by a slow destruction of bile ducts, and progressive
      cholestasis. Prognosis depends on the development of cirrhosis and its complications.
      Ursodeoxycholic acid (UDCA) has been established as standard therapy for PBC and improves
      patients' long-term outcome. However, UDCA is not a uniformly effective drug, and the
      prognosis of PBC patients insufficiently responding to treatment is markedly worse. For
      patients with suboptimal treatment response to UDCA obeticholic acid (OCA) as newly approved
      medication (OCALIVA®) is available as second line treatment.

      Due to the low prevalence and the slowly progressive course of the disease it is very
      difficult to investigate the prognosis of subgroups of PBC patients or to evaluate the
      effectivness of therapeutic interventions on clinical outcomes. Therefore, several national
      or international registries (UK-PBC Consortium or the Global PBC Study Group) were founded to
      better characterize the clinical course of PBC patients.

      Since in Germany a registry for PBC does not exist, the German PBC Cohort is being
      implemented as observational study to collect data on treatment progress and success in
      clinical routine that reflects real world conditions in Germany as closely as possible. The
      effectiveness and safety/tolerability of PBC treatment options (UDCA as standard therapy and
      second-line treatment options like OCALIVA in case of inadequate UDCA treatment response)
      will be evaluated.

      In approximatly 40 sites in Germany routine data is collected. There are no specifications
      for the diagnosis, therapy and monitoring of the PBC patients. The documentation of the
      routine data is carried out alongside with guideline recommended treatment intervals of the
      patients.

      Furthermore, a critical criterion for the German PBC Cohort study is the involvement of a
      sufficient number of gastroenterology specialized practices and outpatient clinics that have
      consciously not been selected based on the strict specifications of a clinical trial and
      which provide routine treatment for PBC patients. In addition, patient access is designed to
      be open. Data will be collected on patient groups that represent a majority of the PBC
      patients in Germany, but who are not being investigated in clinical trials.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Systematic registry</measure>
    <time_frame>from baseline to 36 months after baseline (observational period)</time_frame>
    <description>A primary outcome measure is not applicable as usual, since this data acquisition is performed to built a newly developed systematic registry which serves to describe - for the first time in Germany - the characteristics and the recent state of usual clinical care of the respective population.
Within the 18 months of recruitment and 3 years of individual follow-up for every patient regular analyses will be performed and published, based on a statistical analysis plan which may be yearly updated on request to address the main questions of the responsible PBC consortium.
After the end of data acquisition hepatologic scientists may apply with detailed proposals to further use available data. A scientific consortium will than decided on further analyses of data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comprehensive clinical characterization of German PBC patients</measure>
    <time_frame>from baseline to 36 months after baseline</time_frame>
    <description>i.e. demographics, biochemical markers, ultrasound, transient elastography, stage of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of PBC therapies</measure>
    <time_frame>from baseline to 36 months after baseline</time_frame>
    <description>Characterization of UDCA as first line therapy and characterization of approved second-line treatment options such as OCALIVA.
Furthermore, safety data on the PBC medications used will be systematically gathered and reported on high-level aggregation with regard to any causality with PBC treatment per cohort. The respective results will be reviewed against the known safety profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response to PBC therapies after 12 months and during longer courses of application</measure>
    <time_frame>from baseline to 12 months after baseline and to 36 months after baseline</time_frame>
    <description>To evaluate the natural progression under PBC drug therapy with respect to response to treatment changes in laboratory results (as ratios of the upper/lower limits of normal or differences to BL values) and characteristics of liver function will be described, e.g.:
frequency of hepatic decompensation (occurrence of variceal hemorrhage, ascites, encephalopathy, and/or hepatocellular carcinoma),
frequency of liver transplants,
frequency of deaths in total and from a liver-related cause, and
details on further events of special interest, e.g. for the first time serum bilirubin &gt; ULN and/or alkaline phosphatase &gt; 1.5 ULN, or transient elastography &gt; 9.6 kPa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Application and analyses of existing prognostic PBC scores to provide information on patients' prognosis.</measure>
    <time_frame>from baseline to 36 months after baseline</time_frame>
    <description>Details on typical therapeutic measures in treating PBC and patient compliance will be presented. This allows making a statement on quality of PBC treatment in Germany. Effectiveness will be assessed per cohort and compared between physicians' practices and hospital outpatient departments, aggregating data over all participating sites of the respective structure of health care. This refers to GLOBE score and/or Paris II criteria, frequency of hepatic decompensation or frequency of abnormal surrogate parameter (i.e. alkaline phosphatase, bilirubin, ALAT, ASAT or transient elastography). The respective results will be discussed against the results provided from clinical trials to verify everyday suitability of the different PBC therapies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant Medications</measure>
    <time_frame>from baseline to 36 months after baseline</time_frame>
    <description>Assessment of selected concomitant medications (e.g. symptomatic treatment of pru-ritus)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant Autoimmune Diseases</measure>
    <time_frame>from baseline to 36 months after baseline</time_frame>
    <description>Assessment of selected concomitant autoimmune diseases (e.g. overlap syndrome with autoimmune hepatitis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant Non-Autoimmune Diseases</measure>
    <time_frame>from baseline to 36 months after baseline</time_frame>
    <description>Assessment of selected concomitant non-autoimmune diseases (i.e. cardiovascular disease, non-alcoholic fatty liver disease, metabolic syndrome, chronic kidney diseases)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>PBC</condition>
  <condition>Primary Biliary Cholangitis</condition>
  <arm_group>
    <arm_group_label>Group 1 - Incomplete Responder</arm_group_label>
    <description>Primary Incomplete Responder: PBC patients demonstrating an insufficient response to the standard therapy with ursodeoxycholic acid (UDCA) after a minimum of 12 months of treatment (Paris II criteria).
Secondary Incomplete Responder: PBC patients demonstrating a satisfactory initial response to UDCA after a minimum of 12 months of treatment (Paris II criteria) followed by a re-increase of ALP ≥1.5 ULN, or AST ≥1.5 ULN, or bilirubin &gt;1 mg/dl at any later time point during continuous UDCA-treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Responder</arm_group_label>
    <description>PBC patients demonstrating a satisfactory initial and contin-ued response to UDCA after a minimum of 12 months of treatment (Paris II criteria) without a re-increase of ALP ≥1.5 ULN, or AST ≥1.5 ULN, or bilirubin &gt;1 mg/dl at any later time point during continuous UDCA-treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Patients newly diagnosed for PBC receiving an approved PBC therapy for the first time. Patients are considered to be newly diagnosed if the initial diagnosis took place no later than six months prior to inclusion into the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UDCA</intervention_name>
    <description>Routine data is collected for UDCA therapy.</description>
    <arm_group_label>Group 1 - Incomplete Responder</arm_group_label>
    <arm_group_label>Group 2 - Responder</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>ursodeoxycholic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ocaliva</intervention_name>
    <description>Routine data is collected for OCA therapy.</description>
    <arm_group_label>Group 1 - Incomplete Responder</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>obeticholic acid</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients will be recruited in gastroenterology specialized practices and outpatient
        clinics which provide routine treatment for PBC patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Diagnosis of PBC PBC diagnosis (consistent with AASLD and EASL practice guidelines),
             as demonstrated by the presence of at least two of the following three diagnostic
             factors:

               -  History of elevated ALP levels for 6 months.

               -  Positive anti-mitochondrial antibody (AMA) titer or if AMA negative or in low
                  titer (&lt;1:80) =&gt; PBC-specific antibodies:

                    -  anti-GP210 and/or

                    -  anti-SP100 and/or

                    -  antibodies against the major M2 components [PDC-E2, 2-oxo-glutaric acid
                       dehydrogenase complex (OADC-E2), branched-chain-2-oxo-acid-dehydrogenase
                       complex, (BCOADC-E2)].

               -  Liver biopsy consistent with PBC.

          3. Medication-based treatment with at least one drug approved in Germany for the
             treatment of PBC

          4. Availability of all following essential parameters at the initial diagnosis of PBC
             prior to the initiation of treatment with UDCA, 12 months after initiation of UDCA and
             if applicable at time point of secondary incomplete response:

               -  Platelet count

               -  Alkaline Phosphatase (ALP)

               -  Total Bilirubin

               -  Aspartate aminotransferase (AST/GOT)

               -  Age at initial diagnosis of PBC

          5. Patients must meet criteria of one of the cohorts (group 1/2/3) within this NIS
             according to design

          6. written statement of informed consent

        Exclusion Criteria:

        Current participation in a phase I to IV interventional clinical trial for PBC or
        participation in another PBC registry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Berg, Prof.Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johannes Wiegand, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Trautwein, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>RWTH Aachen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Berg, Prof.Dr.</last_name>
    <phone>+49 341 97 12 330</phone>
    <email>thomas.berg@medizin.uni-leipzig.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johannes Wiegand, Prof.Dr.</last_name>
    <phone>+49 341 97 12 330</phone>
    <email>johannes.wiegand@medizin.uni-leipzig.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Trautwein, Prof.Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Marion Muche, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité-Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Tobias Müller, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal Practice</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Uwe Naumann, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liver Center Checkpoint</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Renate Heyne, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Gastroenterology</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Wolf Peter Hofmann, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Chemnitz</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ulrich Stölzel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Tobias Goeser, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal Practice</name>
      <address>
        <city>Dornstadt</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Nektarios Dikopoulos, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefan Mauss, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Andreas Kremer, Dr. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Josef- Hospital Kupferdreh</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Susanne Beckebaum, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Hans Heinrich Wedemeyer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital J.W. Goethe- Universität</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefan Zeuzem, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal Practice</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Gerlinde Teuber, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christoph Neumann-Haefelin, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Gießen</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Elke Roeb, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenerological-Oncological Practice</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Halle</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexander Zipprich, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liver Center Hamburg - Asklepios Clinic St. Georg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Jörg Petersen, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal Practice</name>
      <address>
        <city>Hameln</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ralf Halle, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHH</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Heike Bantel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Rupp, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenerological Practice</name>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthias Hinz, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Philipp Reuken, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenerological Practice</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Gero Moog, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Rainer Günther, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas Berg, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Johannes Wiegand, Prof.Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MVZ Leverkusen</name>
      <address>
        <city>Leverkusen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Karl- Georg Simon, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal Practice Hepatology</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Kerstin Stein, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Andreas Teufel, Prof.Dr.Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital LMU</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Center Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christina-Maria Jung, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Technical University - Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ursula Tanase, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Hauke Heinzow, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nuremberg</name>
      <address>
        <city>Nuremberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Andreas Weber, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal Practice</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Harald Grümmer, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Martina Müller-Schilling, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal Practice</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Karsten Wursthorn, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonie-Klinikum Schwäbisch Hall</name>
      <address>
        <city>Schwäbisch Hall</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Markus Menges, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christoph Berg, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Eugen Zizer, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Josefs-Hospital</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christoph Sarrazin, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2019</study_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Thomas Berg</investigator_full_name>
    <investigator_title>Prof. Dr. Thomas Berg</investigator_title>
  </responsible_party>
  <keyword>ursodeoxycholic acid</keyword>
  <keyword>UDCA</keyword>
  <keyword>obeticholic acid</keyword>
  <keyword>OCALIVA</keyword>
  <keyword>Cohort</keyword>
  <keyword>observational study</keyword>
  <keyword>Bezafibrat</keyword>
  <keyword>Budesonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

